Feds Push New Meningitis Vaccine

meningitis generic
A government panel has recommended that all college freshmen who live in dorms receive a new meningitis vaccine that lasts years longer than the old one and prevents people from being carriers of the bacteria.

The recommendation Thursday was an about-face from previous policy and was prompted largely by a new vaccine, Menactra, made by Sanofi Pasteur. The new vaccine is effective for more than eight years, while the old one lasted just three to five years. The old vaccine also didn't prevent people from being carriers.

The panel also is advising doctors to give the shot to all 11- to 12-year-old children and that it be provided to at least 4 million children eligible under the federal children's vaccines program.

The recommendations by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices are subject to review by CDC officials. But the panel's recommendations generally are followed and will now go out to physicians.

Because each dose is expected to cost about $100 and only 3,000 cases of meningococcal meningitis are reported each year, "it won't save money," said Mark Messonier, an economist with the CDC who helped develop a cost-effectiveness study of the plan.

"It is a strategy that will save lives," he said.

The action will be welcome to parents of college students since meningitis can spread rapidly through dorms. And it will ease the mind of Lynn Bozof of Marietta, Ga., who has been lobbying for such action.

Her 20-year-old son Evan died of bacterial meningitis in 1998 when he was a student at Georgia Southwestern State University.

Hours after complaining of a headache, he was hospitalized. He died weeks later after suffering complications including damage to his brain, lungs and liver, and amputation of all of his limbs.

Had her family known about the vaccine, "Evan would definitely have been immunized. He would be alive today," Lynn Bozof said.

"If this were a more minor illness, no, I couldn't justify it," said vaccine panel member, Dr. Gregory Poland of the Mayo Clinic in Rochester, Minn. "But this is such a morbid disease, it causes such disruption. Every time there is a case, communities panic, it closes schools down."

"I don't want that to happen to any child - yet you have to be able to pay for it," he added.

Over the years, many health and school officials were reluctant to recommend vaccinating all children because of cost-effectiveness issues. This time there was no opposition to the action of the panel, which advises the CDC. The new shot will become available to doctors next month.

The type of meningitis that spreads through college dorms typically kills only about 300 Americans each year, infecting the membranes around the brain and spinal cord. Since it is spread through contact such as kissing, sharing kitchen utensils and sneezing, people who live in close quarters are most at risk.

While all military recruits have been immunized since the 1980s, it wasn't until college outbreaks of meningococcal meningitis in the late 1990s that health officials started offering the shot to college students, although it did not have the endorsement of the CDC.

College freshmen who live in dormitories are six times more likely than other people to be infected with meningitis, the CDC said. They have the country's highest rate of the disease at 5.1 cases per 100,000.

While the disease is rare, it is devastating. Those who don't die from it often are left with severe complications, such as amputations or brain damage.

Faith Hoenstine of Imler, Pa., was 14 when she contracted bacterial meningitis. She thought she had the flu, but her condition worsened and she spent six months in the hospital. Both of her legs above the knee, her left arm above the elbow and her fingers in her right hand were amputated.

"Don't take a chance - get the vaccine," said Hoenstine, now 18 and a freshman at the University of Pittsburgh at Johnstown, Pa. "If there's anything you can do to prevent something from happening to yourself, why not do it?"

By Daniel Yee